These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 86858)

  • 1. Captopril, angiotensin II, and sodium in blood-pressure regulation.
    Atkinson AB; Brown JJ; Fraser R; Leckie B; Lever AF; Morton JJ; Robertson JI
    Lancet; 1979 May; 1(8126):1140. PubMed ID: 86858
    [No Abstract]   [Full Text] [Related]  

  • 2. Captropril, angiotensin II, and sodium in blood-pressure regulation.
    Hoorntje SJ; Prins EJ; Donker AJ
    Lancet; 1979 May; 1(8126):1140. PubMed ID: 86859
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effects of angiotensin converting enzyme inhibitor SQ 14,225 on the blood pressure, renin-angiotensin-aldosterone system and renal function in patients with malignant hypertension (author's transl)].
    Shionoiri H; Uneda S; Tochikubo O; Ohonishi T; Harada J; Sesoko S; Goto E; Fujishima S; Kaneko Y
    Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):13-22. PubMed ID: 6247528
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension.
    Waeber B; Brunner HR; Wauters JP; Gavras H
    Adv Nephrol Necker Hosp; 1981; 10():111-33. PubMed ID: 6267906
    [No Abstract]   [Full Text] [Related]  

  • 5. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients.
    Gavras H; Brunner HR; Laragh JH; Sealey JE; Gavras I; Vukovich RA
    N Engl J Med; 1974 Oct; 291(16):817-21. PubMed ID: 4371298
    [No Abstract]   [Full Text] [Related]  

  • 6. Interrelations of renin, angiotensin II, and sodium in hypertension and renal failure.
    Gavras H; Oliver JA; Cannon PJ
    Annu Rev Med; 1976; 27():485-521. PubMed ID: 779610
    [No Abstract]   [Full Text] [Related]  

  • 7. Malignant hypertension - the role of the paracrine renin-angiotensin system.
    Fleming S
    J Pathol; 2000 Oct; 192(2):135-9. PubMed ID: 11004688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of malignant hypertension with an angiotensin converting enzyme inhibitor.
    Cottone S; Mangano MT; Fulantelli MA; Cerasola G; Salerno L; Nardi E; Lodato G; Traina C
    Clin Ther; 1989; 11(4):511-20. PubMed ID: 2550135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of aldosterone in experimental hypertension.
    McCaa RE; McCaa CS; Bengis RG; Guyton AC
    J Endocrinol; 1979 May; 81(2):69P-78P. PubMed ID: 222873
    [No Abstract]   [Full Text] [Related]  

  • 10. Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation.
    Brunner HR; Gavras H; Laragh JH
    Prog Cardiovasc Dis; 1974; 17(2):87-98. PubMed ID: 4369198
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin inhibitors for hypertension.
    Gavras H; Gavras I; Brunner HR
    Compr Ther; 1980 May; 6(5):14-8. PubMed ID: 6155240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enalapril treatment in a patient with impaired renal function and intolerance to captopril.
    Lindsjö M; Danielson BG; Weiss L; Wikström B
    Scand J Urol Nephrol Suppl; 1984; 79():99-101. PubMed ID: 6089326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different reactivity to angiotensin II of peripheral and renal arteries in spontaneously hypertensive rats: effect of acute and chronic angiotensin converting enzyme inhibition.
    Guidi E; Hollenberg NK
    J Hypertens Suppl; 1986 Dec; 4(6):S480-2. PubMed ID: 11538668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effects of Sar 1-Ile 8-Angiotensin II in malignant essential hypertension].
    Scarpelli PT; Sproviero R; Corti C; Chegai E; Menniti P; Bigioli F; Lamanna S
    Minerva Nefrol; 1979; 26(3):293-6. PubMed ID: 400447
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of the renin-angiotensin-aldosterone axis by low dose intravenous captopril as a treatment for accelerated phase hypertension.
    Padfield PL; Rademaker M; Atherden SM; Davies E; Edwards CR; Eglen A; Williams BC
    J Hypertens Suppl; 1985 Dec; 3(3):S475-7. PubMed ID: 2856771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of the saralasin test to the treatment of malignant or accelerated arterial hypertension (author's transl)].
    Bonnet F; Corvol P; Thibonnier M; Reach G; Lardoux MD; Milliez P
    Nouv Presse Med; 1980 Nov; 9(41):3075-8. PubMed ID: 7443447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontogenetic role of angiontensin-converting enzyme in rats: thirst and sodium appetite evaluation.
    Mecawi AS; Araujo IG; Rocha FF; Coimbra TM; Antunes-Rodrigues J; Reis LC
    Physiol Behav; 2010 Jan; 99(1):118-24. PubMed ID: 19896959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antihypertensive effect of an oral angiotensin I-converting enzyme inhibitor in two cases with malignant hypertension (author's transl)].
    Mizuno K; Gotho M; Tsutsui K; Yamazaki M; Shigetomi S; Kudo S; Matsui J; Haruyama K; Nakamura I; Toki T; Nagasawa S; Fukuchi S
    Nihon Jinzo Gakkai Shi; 1981 Jan; 23(1):1-12. PubMed ID: 7026848
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. The Captopril Prevention Project (CAPP) Study Group.
    Curr Hypertens Rep; 1999 Dec; 1(6):466-7. PubMed ID: 11041675
    [No Abstract]   [Full Text] [Related]  

  • 20. [Angiotensin converting enzyme--captopril].
    Kaneko Y; Shionoiri H; Uneda S; Fujishima S
    Nihon Rinsho; 1979 Oct; 37(10):3492-8. PubMed ID: 392136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.